Microvesicle-mediated delivery of transforming growth factor β1 siRNA for the suppression of tumor growth in mice

Biomaterials

Volumn 35, Issue 14, 2014, Pages 4390-4400

  Zhang, Yaqin ^a   Li, Limin ^b   Yu, Jianxiong ^b   Zhu, Dihan ^b   Zhang, Yujing ^b   Li, Xihan ^b   Gu, Hongwei ^b   Zhang, Chen Yu ^b   Zen, Ke ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Microvesicle; SiRNA; Systemic delivery; TGF 1; Tumor therapy

Indexed keywords

CELL CULTURE; CELL DEATH; CELL PROLIFERATION; MAMMALS; PATHOLOGY; TUMORS;

CO-IMMUNOPRECIPITATIONS; INHIBITORY EFFECT; INTRAVENOUS INJECTIONS; MICROVESICLE; SIRNA; SYSTEMIC DELIVERIES; TRANSFORMING GROWTH FACTORS; TUMOR THERAPY;

CELL SIGNALING;

ARGONAUTE 2 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; GENE DELIVERY SYSTEM; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUMOR GROWTH;

MURINAE; MUS;

MICROVESICLE; SIRNA; SYSTEMIC DELIVERY; TGF-Β1; TUMOR THERAPY;

ANIMALS; APOPTOSIS; ARGONAUTE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE TRANSFER TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; PHOSPHORYLATION; RNA, SMALL INTERFERING; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNILAMELLAR LIPOSOMES;

EID: 84896700643     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.02.003     Document Type: Article

References (39)

1. Guo J., Fisher K.A., Darcy R., Cryan J.F., O'Driscoll C. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol Biosyst 2010, 6:1143-1161.
2. Ozpolat B., Sood A.K., Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 2010, 267:44-53.
3. Oh S., Kim E., Kang D., Kim M., Kim J.H., Song J.J. Transforming growth factor-beta gene silencing using adenovirus expressing TGF-beta1 or TGF-beta2 shRNA. Cancer Gene Ther 2013, 20:94-100.
4. Barreto J.A., O'Malley W., Kubeil M., Graham B., Stephan H., Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater 2011, 23:H18-H40.
5. Seow Y., Wood M.J. Biological gene delivery vehicles: beyond viral vectors. Mol Ther 2009, 17:767-777.
6. Wrzesinski S.H., Wan Y.Y., Flavell R.A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007, 13:5262-5270.
7. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
8. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-495.
9. van den Boorn J.G., Schlee M., Coch C., Hartmann G. SiRNA delivery with exosome nanoparticles. Nat Biotechnol 2011, 29:325-326.
10. Cocucci E., Racchetti G., Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol 2009, 19:43-51.
11. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002, 2:569-579.
12. Luciani N., Wilhelm C., Gazeau F. The role of cell-released microvesicles in the intercellular transfer of magnetic nanoparticles in the monocyte/macrophage system. Biomaterials 2010, 31:7061-7069.
13. Tian X., Zhu M., Tian Y., Ramm G.A., Zhao Y., Nie G. A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma. Biomaterials 2012, 33:6147-6154.
14. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Urbanowicz B., Branski P., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006, 55:808-818.
15. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell, 39:133-44.
16. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29:341-345.
17. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
18. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
19. Li L., Zhu D., Huang L., Zhang J., Bian Z., Chen X., et al. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS One 2012, 7:e46957.
20. Gibbings D.J., Ciaudo C., Erhardt M., Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009, 11:1143-1149.
21. Wahlgren J., De L.K.T., Brisslert M., Vaziri Sani F., Telemo E., Sunnerhagen P., et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 2012, 40:e130.
22. Shtam T.A., Kovalev R.A., Varfolomeeva E.Y., Makarov E.M., Kil Y.V., Filatov M.V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal 2013, 11:88.
23. Watashi K., Yeung M.L., Starost M.F., Hosmane R.S., Jeang K.T. Identification of small molecules that suppress microRNA function and reverse tumorigenesis. J Biol Chem 2010, 285:24707-24716.
24. Zhang L, Hou D, Chen X, Li D, Zhu L, Zhang Y, et al. Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res;22:107-26.
25. Moore L.D., Isayeva T., Siegal G.P., Ponnazhagan S. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res 2008, 14:4961-4970.
26. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
27. Suzuki E., Kim S., Cheung H.K., Corbley M.J., Zhang X., Sun L., et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007, 67:2351-2359.
28. Nagaraj N.S., Datta P.K. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010, 19:77-91.
29. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99-146.
30. Liu Z., Bandyopadhyay A., Nichols R.W., Wang L., Hinck A.P., Wang S., et al. Blockade of autocrine TGF-beta signaling inhibits stem cell phenotype, survival, and metastasis of murine breast cancer cells. J Stem Cell Res Ther 2012, 2:1-8.
31. Muraoka R.S., Dumont N., Ritter C.A., Dugger T.C., Brantley D.M., Chen J., et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002, 109:1551-1559.
32. Oft M., Heider K.H., Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998, 8:1243-1252.
33. Li J., Zhang Y., Liu Y., Dai X., Li W., Cai X., et al. Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J Biol Chem 2013, 288:23586-23596.
34. Buck A.H., Blaxter M. Functional diversification of Argonautes in nematodes: an expanding universe. Biochem Soc Trans 2013, 41:881-886.
35. Jinek M., Doudna J.A. A three-dimensional view of the molecular machinery of RNA interference. Nature 2009, 457:405-412.
36. Hutvagner G., Simard M.J. Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 2008, 9:22-32.
37. Arteaga C.L. Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 2006, 16:30-37.
38. El-Andaloussi S., Lee Y., Lakhal-Littleton S., Li J., Seow Y., Gardiner C., et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc 2012, 7:2112-2126.
39. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.